Abdollahzade Fard, A and Hosseini Gharalari, F and Roshan Milani, SH and Khalilpour, J (2019) Macrophage migration inhibitory factor antagonist (p425) ameliorates kidney histopathological and functional changes in diabetic rats Antagonista (p425) do fator de inibição da migração de macrófagos (MIF) melhora as alterações histopatológicas e funcionais renais em ratos diabéticos. J.Bras.Nefrol, 41 (3). pp. 315-322.
|
Text
1757.pdf Download (4MB) | Preview |
Abstract
Introduction: It is hypothesized that in- creased macrophage migration inhibi- tory factor (MIF) expression may con- tribute to diabetic nephropathy (DN) pathogenesis. The aim of the present study was to investigate the renal effects of MIF inhibition in a diabetic experi- mental model. Methods: Eighteen male Wistar rats (230 ± 20 g) were divided into three groups: 1) control, 2) diabetic (STZ, 50 mg/kg, dissolved in saline, ip), 3) diabetic + MIF antagonist (p425, 1 mg/kg per day, ip, on the 21th day, for 21 consecutive days). The treatment started since we founwd a significant in- crease in urine albumin excretion (UAE) rate in the diabetic rats in comparison with the control rats. The rats were kept individually in metabolic cages (8 AM-2 PM) and urine samples were collected in the 21 and 42th day. At the end, blood and tissue samples were collected for biochemical (BS, UPE, urine GAG, BUN, Cr, Na, and K) and histological analy- ses. Results: The results of this study showed that MIF antagonist (p425) sig- nificantly decreased urine protein and GAG excretion, urine protein/creatinine ratio, and serum BUN and Cr in the streptozotocin-induced DN in the rats. Pathological changes were significantly alleviated in the MIF antagonist (p425)- administered DN rats. Conclusion: Col- lectively, these data suggested that MIF antagonist (p425) was able to protect against functional and histopathological injury in the DN.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Macrophage Migration-Inhib- itory Factors; Diabetic Nephropathies; Macrophage Activation; Proteinuria; Gly- cosaminoglycans. |
| Subjects: | R Medicine > R Medicine (General) |
| Depositing User: | Unnamed user with email gholipour.s@umsu.ac.ir |
| Date Deposited: | 18 Feb 2020 07:50 |
| Last Modified: | 18 Feb 2020 07:50 |
| URI: | http://eprints.umsu.ac.ir/id/eprint/5867 |
Actions (login required)
 |
View Item |
